{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:07:01Z","timestamp":1771258021252,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Cardiac amyloidosis is a disorder caused by amyloid fibril deposition in the extracellular space of the heart. Almost all forms of clinical cardiac amyloidosis are transthyretin amyloidosis (ATTR) or light chain amyloidosis. 99m technetium pyrophosphate (99mTc PYP scan) has changed the landscape of the non-biopsy diagnosis of ATTR cardiac amyloidosis (ATTR-CA) by providing remarkably high diagnostic accuracy. We examined our experience with PYP scans in patients undergoing workup for ATTR-CA and evaluated the diagnostic workflow in patients with intermediate PYP scan results. Materials and Methods: Retrospective chart review study in which we analyzed data of 84 patients who underwent c-99m pyrophosphate (PYP) SPECT scan for the diagnosis of ATTR-CA from 2017 till 2021 at our institution. We identified three groups: Low uptake (PYPL uptake ratio &lt; 1.2 + visual grade 1\/0), n = 30, Intermediate uptake (PYPI uptake ratio 1.2\u20131.49, visual grade 2\/3), n = 25 and High uptake (PYPH uptake ratio \u2265 1.5 + visual grade 2\/3), n = 29. We reviewed patients\u2019 demographics, medical histories, echo parameters and diagnostic testing including light chain analysis, cardiac magnetic resonance results, and biopsies. Results: Mean patients\u2019 age was 73, male-to=female ratio 3:1, 59% of patients were African American. Cardiovascular comorbidities, cardiac biomarkers (BNP and Troponin) and amyloid-related neuropathy were similar in all groups. A statistically significant difference in septal thickness\/posterior wall thickness and final diagnosis were found between the groups. The distribution of overall diagnostic testing ratios for the PYPI group included serum protein electrophoresis 92%, urine protein electrophoresis 65%, free light chain 80%, CMR 32%, tissue biopsy done in 20% and BM biopsy in 16%, which are similar to the ratios of other groups. Overall, 25% (n = 5, 4 TTR-CA and 1 AL Amyloid) of patients in the PYPI group had a final diagnosis of CA established with additional testing (p = 0.001 vs. other groups). Conclusions: The 99mPYP scan is an accurate noninvasive test for cardiac ATTR-CA. Importantly, 25% of the PYPI group had a final diagnosis of ATTR-CA reiterating that diagnosis needs to be pursued in PYPI cases based on clinical suspicion. Routine evaluation and exclusion of light chain disease and establishing a consistent workflow for amyloid diagnosis and continued education for technologists and readers of PYP scans is key to a successful amyloidosis workup.<\/jats:p>","DOI":"10.3390\/medicina59020378","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T02:04:03Z","timestamp":1676513043000},"page":"378","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Towards a Diagnosis of Cardiac Amyloidosis: Single Center Experience with 99m Technetium Pyrophosphate Planar Imaging and Opportunities for Standardization of Diagnostic Workflow"],"prefix":"10.3390","volume":"59","author":[{"given":"Mariam","family":"Saleem","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Ascension Providence Southfield Hospital, Southfield, MI 48075, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Besher","family":"Sadat","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Texas Medical Branch of Galveston, Galveston, TX 77555, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Van Harn","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Henry Ford Health System, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5837-496X","authenticated-orcid":false,"given":"Karthikeyan","family":"Ananthasubramaniam","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Henry Ford West Bloomfield Hospital, West Bloomfield, MI 48322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/imj.15974","article-title":"Current approaches to the diagnosis and management of amyloidosis","volume":"52","author":"Taylor","year":"2022","journal-title":"Intern. Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12350-013-9800-5","article-title":"Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques","volume":"21","author":"AlJaroudi","year":"2014","journal-title":"J. Nucl. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11886-017-0911-5","article-title":"Transthyretin Cardiac Amyloidosis","volume":"19","author":"Mankad","year":"2017","journal-title":"Curr. Cardiol Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14797\/mdcvj.1163","article-title":"Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis","volume":"18","author":"Martyn","year":"2022","journal-title":"Methodist DeBakey Cardiovasc. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes","year":"2016","journal-title":"J. Card. Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"751293","DOI":"10.3389\/fcvm.2021.751293","article-title":"Cardiac Amyloidosis: A Review of Current Imaging Techniques","volume":"8","author":"Razvi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: A bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","first-page":"42","article-title":"Imaging of cardiac amyloidosis by (99m) Tc-PYP scintigraphy","volume":"18","author":"Papantoniou","year":"2015","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m) Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12350-016-0478-3","article-title":"National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy","volume":"24","author":"Harb","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12350-016-0610-4","article-title":"Standardization of 99m Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis","volume":"25","author":"Bokhari","year":"2018","journal-title":"J. Nucl. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week","volume":"75","author":"Hanna","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s12350-016-0768-9","article-title":"Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes","volume":"25","author":"Vranian","year":"2018","journal-title":"J. Nucl. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jjcc.2019.05.011","article-title":"Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy","volume":"75","author":"Ochi","year":"2020","journal-title":"J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Avalon, J.C., Fuqua, J., Deskins, S., Miller, T., Conte, J., Martin, D., Marano, G., Yanamala, N., Mills, J., and Bianco, C. (2022). Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J. Nucl. Cardiol., 1\u201313. Epub ahead of print.","DOI":"10.1007\/s12350-022-02988-5"},{"key":"ref_19","first-page":"19","article-title":"The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre","volume":"29","author":"Dower","year":"2022","journal-title":"Br. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12149-022-01807-8","article-title":"Comparison of 1-h with 3-h planar 99mTc-pyrophosphate scintigraphy in patients with suspected transthyretin cardiac amyloidosis using SPECT as a reference standard","volume":"37","author":"Saitou","year":"2022","journal-title":"Ann. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., Fontana, M., Gheysens, O., Gillmore, J.D., and Glaudemans, A.W.J.M. (2021). ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2\u2014Evidence Base and Standardized Methods of Imaging. Circ. Cardiovasc. Imaging, 14.","DOI":"10.1161\/HCI.0000000000000029"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12350-020-02328-5","article-title":"Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls","volume":"28","author":"Asif","year":"2021","journal-title":"J. Nucl. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e014645","DOI":"10.1161\/CIRCIMAGING.122.014645","article-title":"Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis","volume":"15","author":"Cuddy","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/378\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:37:22Z","timestamp":1760121442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020378"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020378","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}